

To:



Subject:

E-meeting with Medicines for Europe on 7.10.2020
regarding the IP Action Plan

Virtual meeting with Medicines for Europe on the IP Action Plan 7-10-2020

Participants

- GROW: [Redacted]
- Medicines for Europe: [Redacted]

(Medicines for Europe (MfE) is the association representing manufacturers of generic and biosimilar medicines in Europe).

Main take-aways:

[Redacted]

[Redacted]

[Redacted]

[Redacted]

- **SPC accountability:** there is a need for more transparency and there are procedural issues. The Commission clarified its intention of introducing a unitary SPC and/or a unified granting mechanism.
- MfE expressed the concern that due to national-level instruments of EU member states (i.e. fragmentation), access to medicines is often delayed in Eastern European countries, both when a medicine is invented and when an SPC applies.

[Redacted]

[Redacted]

[Redacted]